Algernon NeuroScience
  • HOME
  • ABOUT
    • Overview
    • Structure & Valuation
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • PIPELINE
    • Overview
    • DMT Program For Stroke
    • DMT Program For Traumatic Brain Injury (TBI)
  • INVEST
  • NEWS & MEDIA
    • News Releases
    • Presentations
    • Events
    • Videos & Articles
  • COMPANY
    • Company
    • Our Team
    • Presentations
    • Contacts
    • FAQ
  • CONTACT
Select Page

Slide New Hope for
Brain Injuries
Algernon is the first company
in the world to investigate
psychedelic DMT for stroke
and traumatic brain injury
Overview Invest

Slide The Potential of DMT DMT is a natural psychedelic that
may promote neuroplasticity in
the brain after injuries like
concussion and stroke
Pipeline

Slide Brain Derived
Neurotropic Factor
DMT increases brain derived
neurotropic factor (BDNF), which
is critical to healing after a stroke
or traumatic brain injury
Pipeline

Slide Human Studies Underway DMT intravenous dose and duration studies are now being conducted
with Phase 2 studies being planned for Fall 2023
Clinical Trials

Slide World's Leading
Specialists
We have leading DMT, stroke
and traumatic brain injury
experts on our team
Program Advisors

Slide There is a Huge Global
Market for Treatment
Stroke Treatment Market = USD $15B TBI Treatment Market = USD $4.5B Invest

Slide Participate in Discovery
and Innovation
Be part of our ground-breaking
brain recovery research and invest
in Algernon NeuroScience today
Overview Invest

Subscribe to Algernon NeuroScience

Sign up today and receive company media releases and updates straight to your inbox.

Success!

Subscribe

  • HOME
  • INVEST
  • ABOUT
  • PIPELINE
  • NEWS & MEDIA
  • COMPANY
  • CONTACT

© Algernon NeuroScience – All Rights Reserved 2023      Privacy Policy